Roche is walking away from tominersen, an experimental treatment for Huntington's disease that the company pursued for more than a decade. According to Endpoints News, Roche has dropped the drug after it performed no better than a placebo in a Phase 2 trial.
The decision, as reported by Endpoints News, followed "plenty of ups and downs" over the years of development. Alongside tominersen, Roche is also ending work on an early-stage Huntington's asset, signaling a broader retreat from its efforts in the disease.
Huntington's disease is a devastating, inherited neurodegenerative condition, and there are no treatments that stop or slow its progression. Drugs like tominersen represented one of the more closely watched attempts to change that, which is part of why the program drew so much attention across its long and bumpy history.
A Phase 2 trial is a mid-stage test designed to show whether a drug actually works in patients. When a treatment fails to beat a placebo — an inactive substitute given to a comparison group — it means patients on the drug did not do measurably better than those on nothing at all. That result is often a fatal blow to a program, and in this case it was.
Roche's exit closes the book on one of the higher-profile bets in Huntington's research. For the patient community and their families, the news underscores how difficult it remains to turn scientific promise into a working therapy — and how even large drugmakers with years invested will cut their losses when the data don't hold up.